Castle Biosciences Q4 2023 GAAP EPS $(0.10) Beats $(0.61) Estimate, Sales $66.12M Beat $56.28M Estimate
Author: Benzinga Newsdesk | February 28, 2024 05:30pm
Castle Biosciences (NASDAQ:
CSTL) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.61) by 83.61 percent. The company reported quarterly sales of $66.12 million which beat the analyst consensus estimate of $56.28 million by 17.48 percent. This is a 72.47 percent increase over sales of $38.34 million the same period last year.
Posted In: CSTL